| 利培酮合并知母皂甙元治疗阴性症状为主的精神分裂症的双盲随机对照研究(英文) |
| |
| 引用本文： | 肖世富,薛海波,李霞,陈超,李冠军,苑成梅,张明园.利培酮合并知母皂甙元治疗阴性症状为主的精神分裂症的双盲随机对照研究(英文)[J].中国神经科学杂志,2011(4). |
| |
| 作者姓名： | 肖世富 薛海波 李霞 陈超 李冠军 苑成梅 张明园 |
| |
| 作者单位： | 上海交通大学医学院附属精神卫生中心老年科; |
| |
| 基金项目： | supported by thegrant of Stanley Medical Research Institute(No.02I-005),USA |
| |
| 摘 要： | 目的探讨知母皂甙元是否能增强利培酮的治疗作用,以及两者联用是否能显著提高阴性症状为主的精神分裂症病人的认知功能。方法本研究采用双盲、安慰剂对照的平行设计方案。研究对象随机分为知利培酮合并母皂甙组(n=41)和利培酮合并安慰剂组(n=39),在治疗前及治疗第2、4、8周,分别对患者进行阳性与阴性症状量表(Positive and Negative Symptoms Scale,PANSS)、韦氏记忆量表(Wechsler Memory Scale,WMS)、韦氏简式智力量表(modified Chinese Wechsler Adult Intelligence Scale,mWAIS)、简明精神量表(Brief Psychiatry Rating Scale,BPRS)和临床疗效总评量表(Clinical Global Impression,CGI)评定。每位患者共随访8周,整个研究持续2年。结果在治疗结束时,两组在PANSS、WMS及mWAIS的减分上无统计学差异,两组间不良事件发生率亦无明显差异。结论知母皂甙不会增强利培酮对阴性症状为主的精神分裂症的治疗作用。给予知母皂甙(200mg/d)合并利培酮(2–...
|
| 关 键 词： | 精神分裂症 知母皂甙 利培酮 临床试验 双盲随机 |
A double-blind,placebo-controlled study of traditional Chinese medicine sarsasapogenin added to risperidone in patients with negative symptoms dominated schizophrenia |
| |
| Shi-Fu XIAO,Hai-Bo XUE,Xia LI,Chao CHEN,Guan-Jun LI,Cheng-Mei YUAN,Ming-Yuan ZHANG Geriatric Psychiatry.A double-blind,placebo-controlled study of traditional Chinese medicine sarsasapogenin added to risperidone in patients with negative symptoms dominated schizophrenia[J].Neuroscience Bulletin,2011(4). |
| |
| Authors: | Shi-Fu XIAO Hai-Bo XUE Xia LI Chao CHEN Guan-Jun LI Cheng-Mei YUAN Ming-Yuan ZHANG Geriatric Psychiatry |
| |
| Institution: | Shi-Fu XIAO,Hai-Bo XUE,Xia LI,Chao CHEN,Guan-Jun LI,Cheng-Mei YUAN,Ming-Yuan ZHANG Geriatric Psychiatry Department,Shanghai Mental Health Center,Shanghai Jiaotong University School of Medicine,Shanghai 200030,China |
| |
| Abstract: | Objective To identify whether sarsasapogenin, a sapogenin from the Chinese medicinal herb Anemarrhena Asphodeloides Bunge,would augment the efficacy of risperidone and significantly improve cognitive functions in patients with negative symptoms dominated schizophrenia.Methods The trial was a double-blind,placebo-controlled,parallelgroup design.The eligible patients were randomized into 2 treatment groups:sarsasapogenin group (sarsasapogenin plus risperidone for 8 weeks,n = 41) and placebo group (risperidone... |
| |
| Keywords: | schizophrenia sarsasapogenin risperidone trial double-blind |
| 本文献已被 CNKI 等数据库收录！ |
|
